Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Current options and future perspectives in the treatment of dyslipidemia
S Muscoli, M Ifrim, M Russo, F Candido… - Journal of clinical …, 2022 - mdpi.com
Low-density lipoprotein cholesterol (LDL-C) plays a crucial role in the development of
atherosclerosis. Statin therapy is the standard treatment for lowering LDL-C in primary and …
atherosclerosis. Statin therapy is the standard treatment for lowering LDL-C in primary and …
Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
Y Wang, D Fang, Q Yang, J You, L Wang, J Wu… - Frontiers in …, 2023 - frontiersin.org
Atherosclerosis is an early pathological basis of numerous cardiovascular events that result
in death or disability. Recent studies have described PCSK9 as a novel target for the …
in death or disability. Recent studies have described PCSK9 as a novel target for the …
Effect of evolocumab in patients with prior percutaneous coronary intervention
RHM Furtado, AA Fagundes Jr, K Oyama… - Circulation …, 2022 - Am Heart Assoc
Background: Patients with prior percutaneous coronary intervention (PCI) are at high
residual risk for multiple types of coronary events within and beyond the stented lesion. This …
residual risk for multiple types of coronary events within and beyond the stented lesion. This …
New biological therapies for low-density lipoprotein cholesterol
Depressed low-density lipoprotein (LDL) cholesterol concentration protects against
atherosclerotic cardiovascular disease. Natural hypocholesterolemia states can have a …
atherosclerotic cardiovascular disease. Natural hypocholesterolemia states can have a …
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON
AJ Lorenzatti, ML Monsalvo, JAG López… - Cardiovascular …, 2021 - Springer
Background Atherogenic dyslipidemia (AD), characterized by increased concentrations of
apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 …
apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 …
Assessing the predictive value of different nutritional indexes for contrast-associated acute kidney injury in patients undergoing percutaneous coronary intervention
L Chen, S Zhang, M Luo, C He, Z You, L Zhang… - Circulation …, 2024 - jstage.jst.go.jp
Background: The link between malnutrition and poor prognosis in cardiovascular disease
has been established but the association between malnutrition and contrast-associated …
has been established but the association between malnutrition and contrast-associated …
Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: a protocol for systematic review and meta …
X Ye, S Wang, Q Wu, Y Lv, Q Lv, J Li, L Li, Y Yang - BMJ open, 2023 - bmjopen.bmj.com
Introduction Coronary heart disease (CHD) is one of the common cardiovascular diseases
that seriously jeopardise human health, and endothelial inflammation and dyslipidaemia are …
that seriously jeopardise human health, and endothelial inflammation and dyslipidaemia are …
[HTML][HTML] Lipoprotein (a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome
Background Many patients require revascularization after index acute coronary syndrome
(ACS). Lipoprotein (a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY …
(ACS). Lipoprotein (a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY …
Intensive Lipid‐Lowering Therapy as per the Latest Dyslipidemia Management Guideline in Predicting Favorable Long‐Term Clinical Outcomes in Patients …
L Tang, H Chen, XQ Hu, ZF Fang, XB Liao… - Journal of the …, 2023 - Am Heart Assoc
Background There are limited data on low‐density lipoprotein cholesterol (LDL‐C) goal
achievement per the 2019 European Society of Cardiology/European Atherosclerosis …
achievement per the 2019 European Society of Cardiology/European Atherosclerosis …